AtaiBeckley, a publicly traded clinical-stage biotechnology company developing mental health treatments, has appointed Michael Faerm as chief financial officer (CFO), effective March 9, 2026.
Anne Johnson, who has served as CFO since 2024, will transition to the role of chief accounting officer upon Faerm’s appointment.
Faerm has more than 25 years of experience across life sciences companies, equity research, and investment banking. He most recently served as CFO at Viracta Therapeutics previously CFO at Harpoon Therapeutics, which was acquired by Merck, and CFO of Artiva Biotherapeutics. He also served in executive and strategic roles at Innoviva, Forest Laboratories, and Regeneron Pharmaceuticals, and has Wall Street experience at Credit Suisse and Wells Fargo Securities, and investment banking with Merrill Lynch. Faerm earned an MBA from Harvard Business School, an MS in civil engineering from Stanford University, and a BS in civil engineering from Columbia University.
Aspargo Labs, a pharmaceutical company utilizing its oral suspension platform to deliver therapeutics, appointed Sam Backenroth as its CFO. Backenroth brings 20 years of senior financial and strategic leadership experience in the biotechnology sector, including serving as CFO for multiple public and private companies across therapeutic areas such as ophthalmology, neurology, immunology, and oncology. Earlier in his career, Backenroth worked as an investment banker. He holds a BS in finance from Touro College in New York.
Publicly traded Bicycle Therapeutics plc appointed Travis Thompson, who joined the company in April 2018 and most recently served as its senior vice president and chief accounting officer, as its CFO. Thompson will continue to oversee finance and accounting functions, and now investor relations. Alethia Young, who stepped down as CFO, will remain with Bicycle for three months and continue as a company advisor.
Thompson previously worked at EY in its life sciences practice supporting a broad range of companies of all sizes and stages of development. He has a BS in economics and accounting from The College of the Holy Cross.
CNS Pharmaceuticals, a publicly traded biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed Steven O’Loughlin as its CFO, effective March 2, 2026.
O’Loughlin brings more than 15 years of senior financial leadership and capital markets experience across public biotechnology companies. Most recently, he served as CFO of Actinium Pharmaceuticals and prior to that was with Protea Biosciences and in investment banking. He holds a BS in finance from Ramapo College.
Cue Biopharma, a publicly traded clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics treatment of autoimmune and inflammatory diseases, announced that Lucinda Warren has been appointed its chief financial and business officer.
She was promoted from chief business officer, a role she held since September 2024. Warren has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to Cue, she served as vice president of business development for Neuroscience and Japan Regionally at Johnson & Johnson and held strategic roles at Janssen Cilag Australia and Janssen Biologics. Warren holds a BS in biological sciences with a minor in neurology from the University of Alberta.
Galderma Group AG, a dermatology company publicly traded on the Swiss stock exchange, announced Luigi La Corte as its CFO, effective May 1, 2026. He will join the company on April 1 to begin a smooth transition with Thomas Dittrich, who will depart to pursue a senior executive opportunity outside the organization.
La Corte brings more than 30 years of international financial leadership experience and most recently served as CFO at Recordati S.p.A. He has also held a range of senior finance leadership roles with GlaxoSmithKline, AstraZeneca, Alliance Unichem, Pladis Food Group, Bain & Company, PepsiCo and Procter & Gamble. La Corte holds a master’s in economics from Luiss University and is a fellow of the Chartered Institute of Management Accountants.
Ocugen, a publicly traded biotech developing gene therapies for blindness diseases, has appointed Rita Johnson-Greene, MBA, as CFO.
Johnson-Greene has more than 20 years of experience, and most recently served as chief operating officer at the Alliance for Regenerative Medicine. Prior to that, she has served in various executive roles with Genetix Biotherapeutics (formerly known as bluebird bio) and Spark Therapeutics, as well as finance, commercial, and sales roles in both North and South America for AstraZeneca. She began her career in strategic consulting with Accenture’s strategy practice and earned her MBA in finance and strategic management from The Wharton School at the University of Pennsylvania, and her undergraduate degree in electrical computer engineering from Drexel University.
Publicly traded Medicus Pharma Ltd., which focuses on developing novel therapeutic assets through Phase II, announced December 1 that Carolyn Bonner, its current president, was also appointed chief financial officer. Bonner has been serving as Acting Chief Financial Officer since September 12, 2025, upon the departure of Jim Quinlan, who resigned for health reasons.
Bonner brings nearly 20 years of experience in the healthcare and life sciences sector, most recently serving as president and CEO of PCL, Inc., a CAP-accredited specialty laboratory with business operations in the United States and United Arab Emirates.
Prior to that, she held roles in business development and corporate development at Rosetta Genomics Ltd. and Inform Diagnostics, Inc. Bonner holds a BS in marketing from West Chester University of Pennsylvania.
Razi Amri, MD, PhD, has been appointed CFO of Oncoinvent, a biotech company developing radiopharmaceuticals for oncology. He most recently served as vice president and head of development strategy and execution for Galapagos NV and brings several years of management consulting experience from McKinsey & Company.
Amri holds an MD and a PhD from the University of Amsterdam and conducted his PhD research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer.
Sana Biotechnology has named Brian Piper its executive vice president, CFO. Sana develops engineered cells as medicines, including a stem-cell cell-derived pancreatic islet cell program for people with type 1 diabetes and an in vivo CAR T program for B-cell related diseases.
Piper most recently served as CFO of Scorpion Therapeutics until its acquisition by Eli Lilly in 2025, and then CFO of Antares Therapeutics, following its spin-off from Scorpion. He has held CFO and financial positions with Prelude Therapeutics, Aevi Genomic Medicine, and Shire Pharmaceuticals, and began his career at Celera Genomics and Otsuka Pharmaceuticals. Piper obtained his MBA from the University of Maryland and his BBA from the University of Notre Dame.
These announcements are from January 26 through February 19, 2026, as posted on BusinessWire, PRNewswire, Yahoo Finance, LinkedIn, SEC documents, or company postings. If your company has an executive appointment announcement related to finance and accounting, please forward to Brandy Fidler at [email protected].